Yes, there is a significant drug interaction between Flexeril (cyclobenzaprine) and Prozac (fluoxetine) that requires caution and monitoring.
The combination of cyclobenzaprine and fluoxetine can lead to dangerous cardiac complications including QT prolongation, torsade de pointes, and serotonin syndrome. This interaction occurs because fluoxetine is a potent CYP2D6 inhibitor that increases cyclobenzaprine levels, and cyclobenzaprine shares tricyclic antidepressant-like properties including cardiac effects 1.
Mechanism of Interaction
Fluoxetine potently inhibits the CYP2D6 enzyme system, which metabolizes cyclobenzaprine. The FDA label explicitly warns that drugs metabolized by CYP2D6 with narrow therapeutic indices should be initiated at the low end of dosing when combined with fluoxetine, and this caution extends for 5 weeks after fluoxetine discontinuation due to its long half-life 1. Fluoxetine can convert up to 43% of normal metabolizers into poor metabolizers, dramatically increasing drug levels 2.
Primary Clinical Risks
Cardiac toxicity is the most serious concern:
- QT prolongation and torsade de pointes: A documented case showed a patient on chronic fluoxetine and cyclobenzaprine developed a baseline QTc of 497 msec (significantly prolonged), which progressed to torsade de pointes and ventricular fibrillation when droperidol was added perioperatively. The QTc normalized to 440 msec within 24 hours of stopping cyclobenzaprine 3.
- The FDA has issued safety warnings that fluoxetine should be used cautiously in conditions predisposing to QT prolongation, specifically including CYP2D6 poor metabolizers and coadministration of CYP2D6 inhibitors 2.
Serotonin syndrome is the second major risk:
- Cyclobenzaprine has serotonergic properties and multiple case reports document serotonin syndrome when combined with SSRIs 4, 5.
- The FDA label warns about combining fluoxetine with other serotonergic drugs and advises caution 1.
Clinical Management Algorithm
If this combination must be used:
Baseline assessment: Obtain ECG to measure QTc interval before starting combination
- QTc >470 msec in men or >480 msec in women is a contraindication
- Check electrolytes (potassium, magnesium) and correct abnormalities
Dosing adjustments: Start cyclobenzaprine at the lowest possible dose (5 mg rather than standard 10 mg) given fluoxetine's inhibitory effects 1
Monitoring schedule:
- Repeat ECG within 1-2 weeks of combination initiation
- Monitor for serotonin syndrome symptoms: agitation, restlessness, tremor, hyperreflexia, diaphoresis, hyperthermia, muscle rigidity
- Continue monitoring if both drugs remain necessary
Avoid additional QT-prolonging drugs: No droperidol, antiarrhythmics, antipsychotics, or other QT-prolonging agents 3
After discontinuation: Remember fluoxetine's effects persist for 5 weeks due to its long half-life, so cyclobenzaprine dosing precautions apply during this entire period 1
Common Pitfalls
- Underestimating fluoxetine's duration of effect: The 1-3 day half-life of fluoxetine and 4-16 day half-life of its active metabolite norfluoxetine mean drug interactions persist for weeks after stopping 1.
- Missing baseline cardiac risk factors: Patients with congenital long QT, family history of sudden cardiac death, or electrolyte abnormalities are at particularly high risk 2.
- Assuming muscle relaxants are benign: Cyclobenzaprine shares the tricyclic structure and many adverse effects of TCAs, including significant cardiac toxicity 3.
Alternative Approaches
Consider non-pharmacologic treatments for muscle spasm (physical therapy, heat, stretching) or alternative muscle relaxants without serotonergic properties or significant CYP2D6 metabolism, such as methocarbamol or tizanidine, which have lower interaction potential.
While one small study showed efficacy of this combination for fibromyalgia 6, the cardiac safety risks documented in case reports 3 and FDA warnings 1 make this a high-risk combination that should only be used when benefits clearly outweigh risks and with appropriate monitoring.